critical in physiological and pathological processes. We show that tyrosine phosphorylation of VEGF receptor 2 (VEGFR2) at Y951 facilitates binding of VEGFR2 to the Rous sarcoma (Src) homology 2-domain of T cell-specific adaptor (TSAd), which in turn regulates VEGFinduced activation of the c-Src tyrosine kinase and vascular permeability. c-Src was activated in vivo and in vitro in a VEGF/TSAd-dependent manner, and was regulated via increased phosphorylation at pY418 and reduced phosphorylation at pY527. Tsad silencing blocked VEGF-induced c-Src activation, but did not affect pathways involving phospholipase C, extracellular regulated kinase, and endothelial nitric oxide. VEGF-induced rearrangement of VE-cadherin-positive junctions in endothelial cells isolated from mouse lungs, or in mouse cremaster vessels, was dependent on TSAd expression, and TSAd formed a complex with VE-cadherin, VEGFR2, and c-Src at endothelial junctions. Vessels in tsad / mice showed undisturbed flow and pressure, but impaired VEGF-induced permeability, as measured by extravasation of Evans blue, dextran, and microspheres in the skin and the trachea. Histamine-induced extravasation was not affected by TSAd deficiency. We conclude that TSAd is required for VEGF-induced, c-Src-mediated regulation of endothelial cell junctions and for vascular permeability.
Vascular endothelial (VE) growth factor (VEGF) promotes migration, proliferation, and organiza tion of endothelial cells to form vascular struc tures during development and in the adult (Koch et al., 2011) . The original designation for VEGF, vascular permeability factor (VPF), indicates its potent regulation of vessel integrity (Senger et al., 1983) . Permeability to solute and proteins is of critical importance both in physiological and pathological conditions (Mehta and Malik, 2006; Vestweber, 2012) . For example, extravasation of fibronectin and other extracellular matrix pro teins in response to VEGF/VPF allows formation of a provisional matrix for angiogenic sprout ing (Dvorak et al., 1999) . Chronic hyperper meability resulting in persistent edema occurs in conjunction with pathologies involving inflammation, such as cancer (Nagy et al., 2008) . Persistent edema interferes with treatment of cancer by elevating the intratumor interstitial pressure leading to poor perfusion and tissue hypoxia (Stohrer et al., 2000) .
Two main mechanisms have been pro posed for induction of VEGFregulated vascular the global vegfr2 / phenotype (Sakurai et al., 2005) . In contrast, mice with an Y1214F mutation survive develop ment and show no obvious phenotype. The pY951 residue in VEGFR2 mediates binding of the T cell-specific adapter (TSAd), which is essential for endothelial cell actin reorgani zation and cell migration in vitro (Matsumoto et al., 2005) , through regulation of cSrc activity (Matsumoto et al., 2005; Ruan and Kazlauskas, 2012) . Activation of cSrc has also been shown to involve the adaptor molecule Grb2-associated binder 1 (Laramée et al., 2007) . Moreover, Y1059 in the VEGFR2 kinase activation loop binds cSrc, which thereby may phosphorylate other tyrosine residues in VEGFR2 (Meyer et al., 2008) . The mechanism whereby VEGF activates cSrc in vivo has however remained unclear.
TSAd is a classical signal adapter molecule, equipped with a central SH2 domain and a Cterminal prolinerich domain, as well as Cterminal tyrosine phosphorylation sites (Spurkland et al., 1998; Choi et al., 1999; Rajagopal et al., 1999; Wu et al., 2000) . In vivo, TSAd is expressed in certain immune cells and endothelial cells (SundvoldGjerstad et al., 2007) . Activation of the T cell receptor promotes complex forma tion between TSAd and the Src kinase family member Lck (SundvoldGjerstad et al., 2005) . Tsad / mice may develop an autoimmune condition with advanced age (Drappa et al., 2003) although the penetrance is variable. Younger unchal lenged mice lack apparent phenotype.
In this study, we show that VEGFR2mediated cSrc ac tivation and subsequent VEGFinduced vascular permeabil ity requires TSAd. VEGF promotes phosphorylation of cSrc at Y418 and dephosphorylation at Y527, and active cSrc is located in focal adhesions and in endothelial cell adherens permeability, namely, formation of transendothelial pores and transient opening of endothelial cell-cell junctions. Trans endothelial pores may be created in a caveolindependent manner from interconnected clusters of vesicles and vacuoles (the vesiculo vacuolar organelle) that traverse the venular en dothelium (Feng et al., 2002) . Endothelial junctions are com posed of tight junctions and endothelial cellspecific adherens junctions. Opening of adherens junctions requires dissolution of homophilic vascularendothelial cadherin (VEcadherin) complexes in response to cRous sarcoma (Src)-dependent tyrosine phosphorylation of VEcadherin (Scheppke et al., 2008) . Rearrangement of the actin cytoskeleton and altered interactions with the extracellular matrix further support the opening of junctions (Vandenbroucke et al., 2008) .
VEGF transduces its effects by binding to receptor tyro sine kinases VEGFR1 and VEGFR2, of which VEGFR2 is believed to be the main signal transducer in endothelial cells (Koch et al., 2011) . Several tyrosine residues in the VEGFR2 intracellular domain have been identified as phosphorylation sites, including Y951, Y1054, Y1059, Y1175, and Y1214 in the human VEGFR2 (Takahashi et al., 2001; Matsumoto et al., 2005 ). Yet other tyrosine residues including Y801, Y996, and Y1008 have been implicated in VEGFR2 signal ing (DougherVermazen et al., 1994; Meyer et al., 2003; Solowiej et al., 2009) . Whereas pY1054 and pY1059 serve as positive regulatory sites, pY1175 binds the adaptor molecules Shb (Holmqvist et al., 2004) and Sck (Warner et al., 2000) , as well as phospholipase C (PLC; Takahashi et al., 2001) . Exchange of the Y1173 residue in mouse VEGFR2 (Y1175 in human VEGFR2) for phenylalanine results in arrested en dothelial cell development and embryonic death, similar to corresponding to major phosphorylation sites in VEGFR2, i.e., pY951, pY1054, pY1059, pY1175, and pY1214 (Matsumoto et al., 2005) . In addition, phosphopeptides were synthesized that included other tyrosine residues implicated in VEGFR2 signaling, such as Y801 (Solowiej et al., 2009 ), Y996 (Dougher Vermazen et al., 1994 , and Y1008 (Meyer et al., 2003) . As shown in Fig. 1 A, the TSAdSH2 domain bound strongly to the pY951 phosphopeptide and much less to the pY1214 phosphopeptide. We conclude that pY951 and its surrounding sequence in VEGFR2 presents a major binding site for TSAd.
To show how cSrc interacts with VEGFR2 and TSAd, we tested binding of a GSTcSrcSH2 probe to the VEGFR2 phosphopeptides, as well as to phosphopeptides representing the five previously reported tyrosine phosphorylation sites on TSAd; pY39, pY260, pY280, pY290, and pY305 (Granum et al., 2008) . The GSTcSrcSH2 probe bound weakly to pY951 and more efficiently to pY1054, which is located on the kinase activation loop of VEGFR2. Mutation of Y1054 to F is not compatible with kinase activity (Matsumoto et al., 2005) . Furthermore, binding of cSrc to the VEGFR2 kinase activation loop is likely to interfere with kinase activity. The strongest binding of GSTcSrcSH2 overall was to the TSAd pY280 peptide, although the pY290 and pY305containing peptides also presented efficient binding sites. (Matsumoto et al., 2005) . To extend these data, we now used a GSTTSAdSH2 fusion protein to probe a filter spotted with phosphopeptides administration of Evans blue in WT and tsad / mice was followed 2 h later by intradermal injection of vehicle or VEGF (100 ng) on the back. Evans blue dye leakage in dorsal skin was assessed after 30 min. Representative images of three independent experiments using two to four mice/genotype each time with similar result. Bar, 5 mm. (B) Quantification of extravasated Evans blue by formamide extraction from skin samples in A, corrected for tissue weight. n = 5 (WT) and 6 (tsad / ) mice/genotype from 2 independent experiments. *, P < 0.05; **, P < 0.01. of the cytoplasmic tyrosine kinase Lck (Granum et al., 2006) . We used GSTcSrcSH3 as a probe to test binding to TSAd prolinerich peptides ( Fig. 1 B) , which showed strong bind ing of cSrcSH3 to several stretches in TSAd, including the prolinerich region around P247 and P271. Based on these data, we propose that TSAd binds to VEGFR2 at Y951 and that TSAd in turn presents several binding sites for the SH2 and SH3 domain of cSrc (see Fig. 1 C for a schematic outline).
Vascular permeability is impaired in TSAd-deficient mice
Because cSrc has been implicated in the regulation of vas cular permeability (Weis and Cheresh, 2005) , we analyzed tsad / mice, which are fertile and apparently healthy, for their ability to respond to VEGF in a classical Miles assay. Evans blue was administered by tail vein injection in mice that received an intradermal bolus of 100 ng VEGF or ve hicle on the back (Fig. 2 A) . Permeability was induced by VEGF in WT mice, but there was a significant decrease in VEGFinduced Evans blue extravasation in tsad / skin ( Fig. 2 B) . There was no change in basal leakage of Evans blue in the kidney, lung, or skin, between WT and tsad / mice (Fig. 2 C) . We furthermore observed a considerable decrease in VEGFinduced extravasation of systemically delivered FITC dextran in tsad / mice (Fig. 2 D) . There was less than a twofold induction of FITCdextran extravasation with VEGF in the tsad / skin, compared with a sixfold induction in the WT skin (Fig. 2 E) . Basal permeability in the absence of VEGF was not affected by TSAd deficiency in this assay (un published data).
VEGF also induced extravasation of fluorophorelabeled microspheres from venules in the WT, but not the tsad / trachea (Fig. 3 A; see Fig. 3 B for quantification). In contrast, histamineinduced extravasation was comparable in the WT and tsad / trachea (Fig. 3 C) , and the tracheal vasculature was similarly perfused in the two genotypes (Fig. 3 D) . Simi larly, the mean arterial blood pressure, blood flow, blood gases, and acidbase balance were not altered in tsad / mice compared with WT mice (Table 1 ). There was also no resulted in an increase in P1 area (Fig. 4 B) and the appear ance of a second peak (P2), both of which were sensitive to lambda phosphatase digestion (bottom). The more acidic isoelectric point (pI) of the P2 pool indicates that apart from being phosphorylated at Y418, this fraction of cSrc is phos phorylated at additional residues.
Analysis for pY527 reactivity showed one major peak (P3) in untreated cells, corresponding to pY527modified, inactive cSrc. Treatment with VEGF led to the enhancement of a P4 peak and, interestingly, a reduction in the P3 peak area (Fig. 4 B) . P3 most likely corresponds to cSrc phosphorylated at Y527, whereas P4 is phosphorylated at Y527 and likely at another residue that is distinct from that in the pY418reactive P2. Both P3 and P4 were removed with phosphatase treatment. However, the antipY527 antibody still detected phosphatase treated protein, possibly from epitopes unmasked by the phos phatase digestion. Analysis for cSrc protein antibody reactivity showed a pattern very similar to that of pY527. It is notable change in pericyte coating or pericyte morphology in the tsad / vasculature (Fig. 3, E and F) . We conclude that TSAd deficiency selectively attenuated VEGFinduced vascular permeability without disturbing blood flow, blood pressure, or pericyte support of the vessels.
VEGF-induced c-Src activation in vitro depends on TSAd
We next investigated how TSAd contributes to VEGFinduced cSrc activation using primary endothelial cells. We used nanofluidic isoelectric focusing (NanoPro), which allows antibodymediated detection of protein expression and post translational modifications in a highly sensitive manner. Cell lysates from human dermal microvascular endothelial cells (HDMECs) treated with or without VEGF for 7 min were analyzed for cSrc pY418 reactivity. As shown in Fig. 4 A, untreated cells contained one major peak in the electrophero gram, corresponding to cSrc phosphorylated at Y418 in an adhesiondependent manner (peak 1, P1). VEGF treatment S-Na + (mmol/l) 144 ± 1 147 ± 1.0
Hemoglobin (g/liter) 116 ± 4 112 ± 5 a Both strains demonstrated slight anesthesia-induced hyperventilation (high PO 2 , low PCO 2 , low base excess, and low total CO 2 ). There were no significant differences between the groups. (C) HDMECs were transfected with control siRNA (si ctr) or different tsad siRNAS followed by stimulation with VEGF for 7 or 15 min. Blotting was performed on total lysates with antibodies against TSAd; phosphorylated proteins c-Src pY418, pY1175 (autophosphorylation site in VEGFR2), pPLC, peNOS, pERK1/2; and against the corresponding total protein pools. Molecular weights in kilodaltons (kD) are indicated to the right. Immunoblotting for 2 microglobulin was used as a control for equal loading. All results are from the same set of extracts run out on when analyzing VEGFinduced signaling in human umbilical vein endothelial cells that were transfected or not with tsad siRNA (unpublished data). Immunofluorescent staining for cSrc pY418 on HDMECs (Fig. 4 D) showed colocalization of activated cSrc with VEcadherin-positive adherens junctions of endothelial cells (Fig. 4 D) and with paxillin in focal adhesions. Importantly, tsad siRNA silencing attenuated detection of cSrc pY418 associated with adherens junctions in control siRNA transfected cells. In contrast, cSrc pY418 was still present in large focal adhesions (Fig. 4 D, arrowheads) in the tsad siRNA transfected cells.
VEGF-induced Src activation in vivo depends on TSAd
To validate the role for TSAd in VEGFinduced cSrc acti vation in vivo, we studied activation of VEGFR2 and cSrc in WT and tsad / mice after systemic delivery of VEGF through tail vein injection. Lungs, which contain 50% endothelial cells, were harvested at different time points after VEGF injection and analyzed by immunoblotting, as shown in Fig. 5 A. VEGF injection allowed very rapid phosphoryla tion of VEGFR2 at Y949 and Y1173 (corresponding to Y951 and Y1175 in the human VEGFR2) in WT as well as tsad / mice. There was no difference in expression levels that P1, corresponding to pY418, was not detected by the cSrc protein antibody, indicating that the cSrc pY418 pool is a minor fraction of the total pool.
Combined, these data show that VEGF induces phosphory lation of the activating Y418 residue, located on the cSrc kinase activation loop, but that VEGF also promotes decreased phos phorylation of the negative regulatory Y527. In addition, VEGF induces additional posttranslational modifications, most likely phosphorylation of tyrosine, serine, or threonine residues of cSrc at several sites, resulting in P2 and P4 in Fig. 4 A.
We examined the effect of tsad siRNAmediated silenc ing in HDMECs. Whereas VEGF induced a threefold increase in cSrc activation (in relation to total Src protein pool) in control siRNAtransfected cells, silencing of tsad using two different tsad siRNAs perturbed cSrc activation, which in creased only marginally or not at all with VEGF treatment (Fig. 4 C) . However, the basal level of cSrc p418 was ele vated in the tsad siRNAtreated cells relative to control siRNAtreated cells. In contrast, tsad siRNA did not affect VEGFinduced VEGFR2 phosphorylation at pY1175 or phosphorylation of PLC, ERK1/2, or endothelial nitric oxide synthase (eNOS). Akt was not induced in the HDMECs under the conditions used here irrespective of transfection of siRNA (unpublished data). Similar data were obtained different gels to optimize separation. Numbers under total c-Src bands indicate fold change in c-Src pY418/total c-Src protein in the different conditions; the c-Src pY418/total c-Src ratio in the unstimulated ctr-siRNA/ sample was set to 1. Representative results of at least three independent experiments are shown. (D) Immunofluorescent staining for VE-cadherin (white), c-Src pY418 (red), and paxillin (green) of HDMEC cultures transfected with control siRNA (si ctr) or tsad siRNA1 (si tsad) followed by stimulation with VEGF for 7 min. Bottom panels show magnification of merged images from boxed regions in the middle row of panels. White line outlines VE-cadherin-positive junctions, arrowheads indicate c-Src p418 localized at adherens junctions in control siRNA cells and in focal adhesions in tsad siRNA cells.. Representative results of at least three independent experiments are shown. Bar, 20 µm. ) with VEGF and lungs were harvested 1 min later. Blotting was performed on total lung lysates using antibodies against VEGFR2 phosphorylation sites pY1175 and pY951, VEGFR2 protein, VE-cadherin and ZO-1. Control for equal loading was done by immunoblotting for actin. Molecular weights in kilodaltons (kD) are indicated to the right. Data are shown for one mouse injected with PBS and two mice injected with VEGF. Representative results of at least three independent experiments. n = 3 mice/genotype. (B) Mice were treated as in A, but lungs were harvested after 20 min after injection (i.v.) of PBS or VEGF. Blotting was performed on total lung lysates using antibodies against c-Src pY418 and c-Src protein.
Immunoblotting for 2 microglobulin (2M) was performed to control for equal loading. Molecular weights in kilodaltons (kD) are indicated to the right. Numbers above lanes indicate fold-change in c-Src pY418/ total c-Src protein, set to 1 for the unstimulated WT sample. Representative results of three separate experiments are shown. (C) WT and tsad / mice were injected (i.v.) with PBS or VEGF, and lungs were harvested 1, 10, and 20 min later. Conversion of l-arginine to nitric oxide (NO) in lung tissue was determined using stoichiometric production of l-citrulline. *, P < 0.05. n = 3 mice/genotype for each time point from 1 experiment.
VEcadherin immunostaining remained uninterrupted in the tsad / cremaster muscle vessels with VEGF treatment (Fig. 7 A) . Image analysis and quantification (Fig. 7 B) showed that the junctional outline moved further away from the junction midline in the VEGFtreated WT vessels, whereas VEGFtreated tsad / junctions remain unaffected compared with basal. The VEGFinduced change in VEcadherin morphology was statistically significant (Student's t test; WT vs. basal, P < 0.013). These data are in accordance with the pattern observed in the isolated endothelial cells from WT and tsad / lungs (Fig. 6 A) .
DISCUSSION
We show that TSAd deficiency is accompanied by loss of VEGFinduced cSrc activation in vitro and in vivo. This is paralleled by an arrest in VEGFinduced vascular permeabil ity, as indicated by the markedly reduced extravasation of Evans blue, 70kD dextran, and 30nm microspheres in the mouse skin and trachea. The vascular permeability arrest ap pears to be specific to VEGF and does not affect histamine induced extravasation. There is also no disturbance in blood flow or blood pressure. TSAd exerts its effect by binding to VEcadherin, VEGFR2, and cSrc in endothelial junctions. These data provide for the first time a mechanism for how VEGFR2dependent permeability is regulated on the molecular level.
Altered vascular permeability is perhaps one of the most significant effects of VEGF, in accordance with its alternative designation VPF (Senger et al., 1983) . Two principal path ways for vascular permeability have been suggested. One in volves VEGFinduced formation of caveolae and the assembly of caveolae into VVOs, thus allowing transendothelial pas sage (Baluk et al., 1997; Dvorak and Feng, 2001) . VVO deficient mouse models are not available and the molecular regulation of VVOs by VEGF remains to be deduced. How ever, caveolin1-deficient mice show increased VEGFR2 tyrosine phosphorylation and enhanced vascular permeability (Lin et al., 2007) . A second mechanism for VEGFregulated vascular permeability involves transient dissolution of adher ens junctions in a VEcadherin-dependent manner (Weis and Cheresh, 2005) . VEGF induces tyrosine phosphorylation of VEcadherin and its binding partners catenin, plakoglo bin, and p120 in vitro (Esser et al., 1998) and in vivo (Weis et al., 2004a; Lambeng et al., 2005) . The effect of VEGF is mediated by the cytoplasmic tyrosine kinases Src and Yes (Eliceiri et al., 1999) . Thus, VEGFinduced cSrc activation has been implicated in the disruption of molecular complexes involving VEGFR2 and VEcadherin/catenin that lead to destabilization of junctions (Weis et al., 2004a,b) directly through cSrc-mediated tyrosine phosphorylation of VE cadherin at Y658 (Wallez et al., 2007) . Activation of focal adhesion kinase in response to VEGF and downstream tyro sine phosphorylation of catenin are additional prerequisites for opening of paracellular junctions (Chen et al., 2012) .
Junctiondependent permeability may also be regu lated through the internalization of VEcadherin, a process of VEGFR2 or the adherens and tight junction proteins VEcadherin and ZO1, respectively, between WT and tsad / samples. Importantly, only WT, but not tsad / , lung samples contained higher levels of cSrc pY418 at 20 min after delivery of VEGF to the circulation (Fig. 5 B) . Indeed, even the basal level of cSrc activity was decreased in the tsad / lung samples.
We further analyzed the consequence of tsad knockout by measuring accumulation of 3 [H]citrulline, an eNOS metab olite (Feng et al., 2010) . Lungs from WT mice harvested after tail vein injection of VEGF showed significant accumulation of 3 [H] citrulline. In the tsad / mouse lungs, accumulation of 3 [H]citrulline still occurred, but with slower kinetics and to a reduced extent compared with WT (Fig. 5 C) .
Persistent endothelial cell junctions in isolated primary tsad / endothelial cells
To show the consequence of TSAd deficiency on adherens junctions, endothelial cells isolated from mouse lungs were treated with VEGF and immunostained for VEcadherin (Fig. 6 A) . WT endothelial cells displayed a relatively con tinuous VEcadherin-positive junctional lining, which was disrupted and rearranged in response to VEGF (see Fig. 6 B for quantification of VEcadherin area under different condi tions). The rearrangement of VEcadherin was at least in part dependent on cSrc, as treatment with a cSrc kinase inhibitor decreased the VEcadherin-positive area in the VEGFtreated WT endothelial cells. In contrast, tsad / endothelial cells revealed no or very limited changes in VEcadherin morphology and there was no change in VE cadherin area with and without VEGF (Fig. 6 B) . Similar results were obtained when analyzing adherens and tight junctions in endothelial cells isolated from WT and tsad / livers (unpublished data).
To show the localization of cSrc pY418 in relation to junctions in the presence and absence of TSAd, we used puri fied lungderived endothelial cells treated or not with VEGF, followed by immunostaining for cSrc pY418 and for VE cadherin. In the basal condition, cSrc pY418 was localized in the cell periphery. VEGF treatment induced translocation of active cSrc into VEcadherin-positive adherens junctions. In contrast, in the tsad / endothelial cells, the cSrc pY418 immunostaining was similarly localized in the presence and absence of VEGF (Fig. 6 C) . Combined, these data show that TSAd is required for VEGFinduced cSrc activation in en dothelial cell junctions. The underlying mechanism involves complex formation between VEcadherin and TSAd, to gether with VEGFR2 and cSrc, which was observed in WT but not in tsad / lung lysates (Fig. 6 D) .
TSAd-dependent regulation of endothelial junctions in vivo
We further studied VEcadherin-positive junctions in vivo, in wholemounts of the mouse cremaster muscle (Fig. 7 A) . Treatment of this very thin and accessible muscle with VEGF through superfusion for 30 min caused rearrangement of VEcadherin-positive junctions in the WT venules. In contrast, Activation of eNOS and enhanced NO release by differ ent inflammatory stimuli, including VEGF, has been shown to lead to increased microvascular permeability (Sessa, 2009 ). Thus, VEGF fails to induce vascular permeability in eNOS knockout mice (Fukumura et al., 2001 ). Activation of eNOS in response to VEGF and histamine has been shown to involve PLC and subsequent activation of protein kinase C, as well as AKT/protein kinase B (PKB; Fulton et al., 1999; Fukumura et al., 2001; Di Lorenzo et al., 2009) . TSAd has been reported to couple to PLC and PI3Kregulated pathways in endo thelial cells (Wu et al., 2000) . We previously showed that VEGF still induced activation of PLC and PI3K/Akt in cells expressing a mutated Y951F VEGFR2, i.e., in the absence of engagement of TSAd (Matsumoto et al., 2005) . Our data are in accordance with studies by Shibuya and coworkers dem onstrating that Y1175 but not Y951 in VEGFR2 is required for binding and activation of PLC (Takahashi et al., 2001 ). Activation of eNOS involves phosphorylation on at least six residues: serine, threonine, and tyrosine (Durán et al., 2010) . The fact that acetylcholine induces the same pattern of eNOS phosphorylation as VEGF but still fails to induce permeability strongly indicates that phosphorylation is not sufficient to mediate full eNOS activation. Indeed, additional events, such as translocation of eNOS from the membrane to the cytosol are required for eNOSmediated permeability (Durán et al., 2010) . The intact VEGFinduced eNOS phosphorylation in tsad siRNAtransfected cells (Fig. 2 A) , but partial accumula tion of 3 [H]citrulline in tsad / lungs (Fig. 5 C) , is compatible in that initial steps in the eNOS-NO-permeability pathway are operating in the absence of TSAd.
that can occur in a clathrindependent manner (Xiao et al., 2005) . Moreover, cSrc-dependent activation of Vav and p21activated kinase (PAK) leads to serine phosphorylation of VEcadherin at S665 (Gavard and Gutkind, 2006) and internalization of VEcadherin. VEcadherin immuno staining in endothelial cell cultures in vitro (Fig. 6 ) and vessels in vivo (Fig. 7) show rearrangement of adherens junctions in response to VEGF in the WT, but not in the tsad / condition. Whether the VEGFinduced effect in the WT cells was accompanied by VEcadherin internalization was not addressed.
The response to histamine in extravasation of fluorescent micropheres was not impaired in tsad / mice (Fig. 3 C) , which is in agreement with previous data showing that Src activity is dispensable for histamineinduced vascular permeability (Eliceiri et al., 1999) . This indicates that junctions are not generally affected by the loss of TSAd expression. We lack reagents to perform immunostaining for TSAd on mouse tis sues. However, in lysates from WT lungs, which contain 50% endothelial cells, we could show that TSAd exists in complex with VEcadherin, VEGFR2, and cSrc, and thus that TSAd is at least partially localized in junctions. We have shown before that TSAd engages in transient complex formation with both VEGFR2 and cSrc. TSAd's SH2 domain binds directly to VEGFR2 phosphorylation sites, and the Prorich domain binds to cSrc (Fig. 1) . It is possible that the TSAd-VE cadherin interaction is indirect and dependent on VEGFR2, which is complexed to VEcadherin (Tzima et al., 2005) . Collectively, these data reinforce a critical role for TSAd in regulation of vascular permeability.
(Millipore); sheep anti-human TSAd, goat anti-mouse VEGFR2, and goat anti-mouse VECadherin (R&D Systems); goat anti-human VEcadherin, goat anti-actin, rabbit anti-cSrc, rabbit antipaxillin, and mouse anti PLC (Santa Cruz Biotechnology, Inc.); Armenian hamster anti-mouse CD31 clone 2H8 (Thermo Fischer Scientific). Dylight 594 lectin was ob tained from Vector Laboratories. Fluorescently labeled second antibodies were derived from donkey (Invitrogen).
TSAdSH2 was amplified by PCR from an intact cDNA clone (Granum et al., 2006) and cloned into the BamHI-NotI pGEX6P1 (GE Healthcare). SrcSH2 cloned into pGEX2T was a gift from J.T. Parsons (University of Vir ginia, Charlottesville, VA; Flynn et al., 1993) . GST-SH2 domain constructs were expressed in Escherichia coli BL21 (DE3) and GSTfusion protein produced ac cording to the description by the manufacturer of the vector. Fusion protein was purified by Glutathione Sepharose 4B beads (GE Healthcare) in a batch mode as described by the manufacturer. GSTSH2 domains were eluted from beads using glutathione, and protein concentration was measured by Nano Drop spectrophotometry (Thermo Fischer Scientific) at 280 and a theoreti cally obtained extinction coefficient (ProtParam). Recombinant mouse VEGFA165 was purchased from PeproTech.
TSAd nomenclature and mouse model. TSAd is also known as Lck associated adapter protein (LAD; Choi et al., 1999) , Rlk/Itk binding pro tein (Rajagopal et al., 1999) , and VEGF receptor-associated protein (Wu et al., 2000) . The mouse TSAd gene is designated sh2d2a. For clarity, we designate both human and mouse gene and protein as TSAd. C57BL/6 WT mice were purchased from B&K Scanbur.Tsad / mice (Rajagopal et al., 1999) in the C57BL/6 background (backcrossed 10 generations) were pro vided by J.A. Bluestone (University of Chicago, Chicago, IL), and sub sequently propagated at the local animal facility under laminar airflow conditions with a 12h light/dark cycle at a temperature of 22-25°C. All animal work was approved by the Uppsala University board of animal experimentation. Analyses were performed on mice of ~6 mo of age.
Peptide spot array analysis. Peptide arrays were synthesized on nitro cellulose membranes using a MultiPep automated peptide synthesizer (INTAVIS Bioanalytical Instruments) as previously described (Kramer et al., 1999; Frank, 2002) . Peptide array membranes were probed with GSTtagged SH2 domains (2-40 µg/ml) and blotted with mouse antiGST antibody (Santa Cruz Biotechnology, Inc.) and anti-mouse HRP secondary antibody followed by chemiluminescent detection. NanoPro Technology. HDMECs treated with VEGF for 7 min at 37°C were lysed in RIPA buffer containing phosphatase and protease inhibitors (ProteinSimple). The cell lysates were clarified by centrifugation, and pro tein concentration was determined using the BCA Protein Assay kit (Thermo Fischer Scientific). Samples were run in triplicate. Lysates were mixed with ampholyte premix (pH 5-8) and fluorescent pI standards (pI Standard Ladder 3) before being loaded into the NanoPro1000 system (ProteinSimple) for analy sis. Isoelectric focusing was performed in capillaries filled with a mixture of cell lysate (0.05-0.1 mg/ml protein), fluorescently labeled pI standards, and ampholytes. The separated proteins were crosslinked to the capillary wall using UV light followed by immunoprobing with antiSrc pY418 (Invitro gen), antiSrc pY527 (Cell Signaling Technology), and antiSrc (Abcam) antibodies. HSP70 antibodies were run in parallel for normalization. HRP conjugated secondary antibodies (anti-rabbit HRP and anti-mouse HRP; ProteinSimple) were used to detect the signal. The signal was visualized by ECL and was captured by a chargecouple device camera. The digital image was analyzed and peak area quantified with Compass software (Protein Simple). Some samples were enzymatically dephosphorylated by incubating 8 µg cell lysate with 125 units lambda phosphatase (14-405; Millipore), for 1 h at 37°C.
Western blotting. Cells were lysed either in NP40 buffer (HDMECs and human umbilical vein endothelial cells; 20 mM Tris HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1% NP40, 2 mM EDTA, 500 µM Na 3 VO 4 , 1% aprotinin, Several VEGFR2coupled pathways have been impli cated in cSrc activation, including the scaffold protein GAB1, which was implicated in most if not all pathways induced by VEGF (Laramée et al., 2007) . Endothelial specific knockout of GAB1 is compatible with developmen tal angiogenesis, but leads to impaired ischemiainduced adult angiogenesis and increased apoptosis of endothelial cells due to loss of hepatocytegrowth factor signaling (Zhao et al., 2011) . Furthermore, VEGFactivation of Akt and eNOS are impaired in GAB1 knockout endothelial mice (Lu et al., 2011) . GAB1 deficiency therefore appears to affect signaling in a more general way than TSAd defi ciency, by disturbing a wider spectrum of endothelial biol ogy in response to several input stimuli. Moreover, Meyer et al. (2008) showed that cSrc binds to VEGFR2 at Y1057 (Y1059 in the human VEGFR2), which is located on the kinase activation loop. It is expected that binding of signal ing molecules to the activation loop would disturb kinase activation. We have not been able to address the role of Y1057/1059 in cSrc activation as an Y1059F mutant of VEGFR2 is an inactive kinase in our hands (Matsumoto et al., 2005) . Furthermore, the phosphopeptide dot blot analysis in the current study (Fig. 1 A) showed binding of cSrc SH2 to Y1054, but not to Y1059. We do not formally exclude the potential contribution of these VEGFR2 resi dues in cSrc activation, but believe that their primary role is in regulation of VEGFR2 kinase activity. cSrc activation by VEGF in primary endothelial cells involved both in creased phosphorylation at the positively regulating Y418 and dephosphorylation at the negatively regulating Y527 (Fig. 1 B) . In agreement, a dominant-negative Cterminal Src kinase (CSK), which prevents phosphorylation of cSrc at Y527 by WT CSK, promotes VEcadherin phosphorylation at Y658, 685, and 731 (Adam et al., 2010) . We also noted that VEGF induces additional posttranslational modifica tions of cSrc; possibly phosphorylation as judged from the more acidic pI of the modified cSrc. In accordance, other growth stimuli, such as PDGF, have been shown to induce additional phosphorylation to Y418 and Y527 in cSrc (Roskoski, 2005) . The role of these additional sites remains to be shown.
We conclude that TSAd is essential for VEGFinduced cSrc activation and translocation to endothelial junctions, and for subsequent regulation of vascular permeability. Im portantly, our data suggest that TSAd may be a useful drug target for the specific modulation of excess VEGFinduced permeability in pathological conditions.
MATERIALS AND METHODS
Antibodies, recombinant proteins, and growth factors. The following antibodies were used: rabbit antidesmin and  2 microglobulin (Abcam); rat anti-mouse CD31 and mouse antieNOS pS1177 (BD); phosphoVEGFR2 (Tyr1175), phosphoVEGFR2 (TyrY951), and phosphop44/42 (Tyr202/ Tyr204; Cell Signaling Technology); rabbit antiphospho cSrc (Tyr418), TRITCconjugated phalloidin, and rabbit anti-ZO1 (Invitrogen); goat anti-Armenian hamster Cy3 (Jackson ImmunoResearch); rabbit antiNG2 (www.freidok.uni.freiburg.de/volltexte/6433), 100 nm fluorescent micro spheres were injected together with histamine (125 µg/mouse) in a volume of 100 µl; perfusion was performed after 2min circulation. Tracheas were dissected and fixed in 4% PFA in PBS for 2 h, and then permeabilized with 0.3% Triton X100 in PBS for 30 min. They were incubated overnight at 4°C with rat anti-mouse CD31, followed by staining with Alexa Fluor 555 goat anti-rat antibody to visualize the vasculature. Extravasated microspheres in the region of postcapillary venules between cartilage rings were analyzed with confocal microscopy.
Isolation of lung endothelial cells. To isolate murine endothelial cells, the lung of three 3-4wkold mice were removed, finely minced, and digested with 1% Worthington type 1 collagenase in Dulbecco's PBS with calcium/ magnesium for 60 min at 37°C. Digested tissues were further broken apart by being passed through a 14gauge needle 4-5 times and then filtration through a 70µm cell strainer. The filtrate was incubated for 40 min at 4°C with 50 µl of magnetic beads (Invitrogen) that had been conjugated with anti-mouse CD31 antibody. Cells with beads attached were collected using an MPC mag net (Invitrogen) and washed 6 to 8 times with PBS/BSA. The cells were grown in DME basal medium with 4.5 g/l glucose, 1 mM sodium pyruvate, 2 mM glutamine, 1 mM nonessential amino acids, 20% FBS, 50 mg/500 ml ECGS (Biomedical Technologies, Inc.), 0.1 mg/ml heparin, and antibiotic. The purity was >95%, as determined by counting of VEcadherin-positive cells.
eNOS activity assay. eNOS activity was determined using a Nitric Oxide Synthase (NOS) Assay kit (EMD) that measures conversion of radioactive [ 3 H]larginine to [ 3 H]lcitrulline. This reaction involves a fiveelectron oxidation of a guanidinonitrogen of larginine to nitric oxide (NO), together with the stoichiometric production of lcitrulline. Mouse lung tis sues were harvested en bloc and homogenized in 20 ml icecold 1X homog enization buffer containing 25 mM TrisHCl, 1 mM EDTA, and 1 mM EGTA, pH 7.4, per gram of tissue. After centrifuge for 5 in at 4°C, the freshly prepared supernatants were used for the assay as described in the manufacturer's protocol. A small aliquot from each sample was used to de termine protein concentration, and 10 µg of protein lysates were used per reaction. Lung tissues from three WT and tsad / mice were used for each time point (1, 10, and 20 min). Experiments were performed in triplicate. All values are presented as mean ± SEM. A value of P < 0.05 between ex perimental groups was considered to represent a significant difference (*).
Blood parameter measurements. The blood flow measurements were performed with a microsphere technique, as previously described and evalu ated (Carlsson et al., 1996) . WT and tsad / mice aged 3-6 mo were anes thetized with Isoflurane and placed on an operating table heated to body temperature (38°C). Polyethylene catheters were inserted into the ascending aorta, via the right carotid artery, and into the right femoral artery. The for mer catheter was connected to a pressure transducer (PDCR 75; Druck) to allow continuous monitoring of the mean arterial blood pressure, which was allowed to stabilize for 20-25 min. Approximately 10 5 nonradioactive mi crospheres (EZTrac; Triton) with a diameter of 10 µm were injected for 10 s via the catheter with its tip in the ascending aorta. Starting 5 s before the microsphere injection, and continuing for a total of 60 s, an arterial blood reference sample was collected by free flow from the catheter in the femoral artery at a rate of 0.10 ml/min. The exact withdrawal rate in each experi ment was confirmed by weighing the sample.
Arterial blood was then collected from the catheter in the femoral artery and analyzed for blood pH, pCO 2 , pO 2 , oxygen saturation, SHCO 3  , base excess, SNa + , SK + , hematocrit, and hemoglobin concentration with an iStat (Abbott Scandinavia). The cassette used for this analysis requires 90 µl of whole blood. Arterial blood was also used for determination of blood glucose concentrations (Medisense Test Reagent Strips; MediSense) and for serum insulin determinations with ELISA (Rat Insulin ELISA; Mercoedia AB).
The animals were euthanized, and the organs referred to in Table 1 were carefully dissected free from fat, blotted, and weighed. The micro spheres in the organs and the arterial blood reference sample were visualized 10 µg/ml leupeptin, and 1 mM phenylmethyl sulfonylfluoride) or in RIPA buffer (lung tissue; commercial RIPA buffer from ProteinSimple). The pro tein concentration was measured using the BCA protein detection kit (Thermo Fisher Scientific) and adjusted for equal loading. Lysates were heated to 95°C in sample buffer (59 mM TrisHCl, pH 6.8, 1.5% SDS, 4.35% glycerol, 4% mercaptoethanol, 0.0025% bromophenol blue). Proteins sepa rated by NuPage Novex 4-12% BisTris Gel (Invitrogen) were transferred to nitrocellulose (HybondC Extra; GE Healthcare), blocked in 5% BSA/PBS, 0.2% Tween 20, followed by incubation with primary and HRPconjugated secondary antibodies in 1% BSA/PBS, 0.2% Tween 20. Information on the primary antibodies is given above. Blots were developed using ECL (GE Healthcare) and exposure to Hyperfilm ECL (GE Healthcare).
For the lung lysate analyses, WT and tsad / mice were sacrificed 1 or 20 min after mice received tailvein injection of 5 µg VEGF, followed by quick removal of lungs, which were snapfrozen before lysis.
When indicated, cells were transfected with siRNA before immuno blotting. Cells were then seeded in gelatincoated 6wells (10 5 cells/well) and transfected with 60 pmol siRNA targeting tsad or stealth RNAinegative ctr (Invitrogen) using the Lipofectamine RNAiMAX transfection reagent (Invitro gen). Experiments were done 48 h after siRNA transfection. The following tsad siRNA were used: sitsad1 5GAGGACCGAAGAAUCAAACUUUGGA3 and sitsad 3 5CCAGTACAGCCCAATCATCAA3.
Immunostaining. Primary ECs (HDMECs) or ECs or isolated lung or liver endothelial cells) were cultured on slides precoated with 1 mg/ml col lagen. The cells were treated with or without 50 or 100 ng/ml VEGFA165 for 10 min before fixation. The endothelial cells were fixed in 4% parafor maldehyde in PBS for 20 min, and permeabilized with 0.1% Triton X100 in PBS for 30 min, followed by immunofluorescence staining.
For immunostaining of the cremaster muscle, tissues were retrieved after perfusion via aorta with prewarmed sterile saline solution (37°C), and then with 1% PFA. The muscle tissue was dissected and fixed in 4% PFA in PBS for 20 min, washed six times with PBS, and permeabilized with 0.1% Triton X100 in PBS for 30 min. The tissues were immuno stained with goat anti-mouse VEcadherin antibody (R&D Systems), fol lowed by staining with Alexa Fluor 488 donkey anti-goat antibody to visualize VEcadherin on venules.
Miles assay. 30 min before Evans blue injection, mice were subjected to i.p. injection with pyrilamine maleate salt (4 mg/kg body weight in 0.9% saline; SigmaAldrich) to inhibit histamine release. Mice were injected in the lateral tail vein with 100 µl Evans blue (0.5% Evans blue in sterile saline; SigmaAldrich), which was allowed to circulate for a total of 2 h. VEGF A165 (100 ng in 50 µl/site) or sterile saline were injected intradermally. 30 min after VEGF injection, the dorsal skin was excised and Evans blue was extracted by immersion in formamide buffer. To determine basal extravasa tion, kidney, lung, and skin were excised. The amount of Evans blue in each tissue sample was quantified by spectrometry at 620 nm (EMax microplate reader; Molecular Devices).
FITC-dextran perfusion assay.
To analyze VEGFinduced acute permeabil ity responses, a 50 µl solution of VEGFA165 (100 ng, diluted in sterile saline) or saline alone was injected i.d. in the ear, followed by injection of FITC dextran. 50 µl 70kD FITCdextran (50 mg/ml in PBS; SigmaAldrich) was administered systemically via tail vein injection. 30 min later, specimens were harvested and fixed in 4% paraformaldehyde, followed by confocal microscopy. To determine basal permeability of microvessels, specimens were harvested and analyzed 2 h after injection of FITCdextran.
Microsphere extravasation assay in mouse trachea. 20 µl of 30 nm FluoroMax Green Aqueous Fluorescent microspheres (Thermo Fisher Sci entific) together with 80 µl solution of VEGFA165 (3 µg/mouse) or saline were administered by tail vein injection. 30 min later, intravascular micro spheres were perfused by 1% PFA in PBS via the left ventricle. For the hista mine extravasation analysis, which was performed according to protocol Image analysis of VE-cadherin immunostaining of cremaster muscle vessels. Cremaster muscle tissue was harvested after vehicle or VEGF superfusion for 30 min, fixed, and immunostained with antibodies against VEcadherin. Images were acquired using a Zeiss LSM700 confocal micro scope (63× NA 1.4 objective). From a Z series of confocal images of VE cadherin through a vessel, areas showing the junctions between endothelial cells that were aligned with the imaging plane were extracted and a maximum projection made in the Z axis, on a single side of the vessel and excluding the edges of the vessel. A binary image showing the junction was then generated by intensity thresholding. Breaks in the junction were joined semiautomatically. The midline along the junction was generated by eroding the binary image to a line (skeletonization) and spurs were removed by erosion, producing a con tinuous midline around each cell. In addition the outline of the binary image was generated. Images showing distances from the midline were generated using a Euclidean distance transform and a population of widths, taken as the shortest distance of each pixel on the outline to the midline, was then ob tained from the distance transform. Where disconnected parts of the junction had been joined, the width was recorded as zero. The widths from individual pixels from different vessels were combined and displayed in a histogram. To eliminate any differences in the length of the outlines the distribution of widths was normalized. The histogram shows the frequency of different widths in microns as percentage of the whole population for each experimental group. Software was based on a Semper6p kernel (Synoptics).
Statistical analysis.
Statistical significance between the groups was calcu lated using Student's twotailed t test or Mann Whitney test. A pvalue < 0.05 was considered significant. *, P < 0.05; **, P < 0.01, ***, P < 0.001.
